Invesco Biotechnology & Genome ETF (PBE)

NYSEARCA: PBE · IEX Real-Time Price · USD
+0.57 (0.99%)
Sep 27, 2023, 4:00 PM EDT - Market closed
Assets $241.69M
Expense Ratio 0.59%
PE Ratio 15.39
Shares Out n/a
Dividend (ttm) $0.01
Dividend Yield 0.02%
Ex-Dividend Date Jun 20, 2023
Payout Ratio 0.37%
1-Year Return +1.56%
Volume 7,113
Open 57.51
Previous Close 57.48
Day's Range 57.51 - 58.07
52-Week Low 57.07
52-Week High 68.50
Beta n/a
Holdings 32
Inception Date Jun 23, 2005

About PBE

Fund Home Page

The Invesco Biotechnology & Genome ETF (PBE) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a tiered equal-weighted index of companies principally engaged in biotechnology and genetic engineering. PBE was launched on Jun 23, 2005 and is issued by Invesco.

Asset Class Equity
Category Health
Stock Exchange NYSEARCA
Ticker Symbol PBE
ETF Provider Invesco
Index Tracked Dynamic Biotech & Genome Intellidex Index (AMEX)

Top 10 Holdings

48.00% of assets
Name Symbol Weight
Amgen Inc. AMGN 5.55%
Vertex Pharmaceuticals Incorporated VRTX 5.33%
United Therapeutics Corporation UTHR 5.29%
Regeneron Pharmaceuticals, Inc. REGN 5.26%
Gilead Sciences, Inc. GILD 5.26%
Biogen Inc. BIIB 5.21%
BioMarin Pharmaceutical Inc. BMRN 5.17%
Incyte Corporation INCY 4.86%
Neurocrine Biosciences, Inc. NBIX 3.10%
Catalent, Inc. CTLT 2.98%
View More Holdings


Ex-Dividend Amount Pay Date
2023-06-20 $0.01407 2023-06-23
2020-03-23 $0.02898 2020-03-31
2018-09-24 $0.00207 2018-09-28
2017-06-16 $0.21532 2017-06-30
2017-03-17 $0.05552 2017-03-31
2016-12-16 $0.1208 2016-12-30
Full Dividend History


This Week in ETFs: Invesco Makes Changes to 35 Funds

A total of nine funds launched during the week ending Sept. 1, thus a dip after the 17 ETF launches last week but not unusual in the leadup to a holiday weekend.

26 days ago - ETF Trends

PBE Offers Exposure to Surging Catalent Stock

Shares of Catalent (CTLT) are surging on Friday after the contract pharmaceuticals manufacturer provided an update on its full-year outlook and past-due financials. Catalent stock is up over 17% in ea...

Other symbols: CTLT
4 months ago - ETF Trends

Invesco's Rene Reyna on Biotech's Rally and the Potential for Future Growth

Biotech has had a strong rally since June, when fortune for the sector abruptly pivoted after months of underperformance.   The sector peaked in early 2021 but struggled to continue the momentum, desp...

Other symbols: IBBQ
1 year ago - ETF Trends

Biotech ETFs Benefit From Moderna Dual Booster Shot News

As the stock market attempts to reverse the recent pullback this month, Moderna shares climbed higher on Thursday after the company announced that it's creating a dual-purpose vaccine booster shot tha...

Other symbols: MRNA
2 years ago - ETF Trends

Could Biotech ETFs Get Another Boost From JNJ News?

This has been a pivotal week for biotech news, as Johnson & Johnson said Wednesday that a booster shot of its COVID-19 vaccine generated a promising immune response in early stage clinical trials. Thi...

Other symbols: BIB
2 years ago - ETF Trends

Biotech ETFs Are Already Benefitting from Pfizer Vaccine's Full Approval

There could be big gains ahead for biotech ETFs, as the Food and Drug Administration on Monday fully approved the Pfizer and BioNTech coronavirus vaccine, making it the first vaccine in the U.S. to be...

Other symbols: BIB
2 years ago - ETF Trends

9 Best Biotech ETFs to Play High-Octane Trends

Biotechnology is a dynamic but often volatile industry. These biotech ETFs provide a lower-risk way to invest in the space.

2 years ago - Kiplinger

Will Biotech ETFs Benefit from Biogen's New Alzheimer's Drug?

Biotech investors may have reason to celebrate this week, as the FDA approved Biogen's Alzheimer's disease drug Aducanumab on Monday, ushering in the first medication to be allowed by U.S. regulators ...

Other symbols: BBHFBT
2 years ago - ETF Trends

5 Top ETFs With Exposure To Biogen

For the first time in 18 years, there was a new treatment for Alzheimer's Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that can reduce the clinical dec...

2 years ago - Benzinga

Biopharma Here to Stay: The Long-Term Case for the PBE ETF

The coronavirus pandemic could be a long-term positive for biopharma companies and the Invesco Dynamic Biotechnology & Genome ETF (PBE). PBE tracks the Dynamic Biotech & Genome Intellidex Index, which...

2 years ago - ETF Trends

3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover

The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexio...

Other symbols: BBHFBT
3 years ago - Benzinga

2 Biotech Funds Poised for a Healthy Breakout

Biotech stocks are likely to remain in focus through year end amid news surrounding COVID-19 vaccines and treatments.

Other symbols: IBB
3 years ago - Investopedia

3 Health Care ETFs Where Components Are Enduring Downgrades

After setting scintillating paces earlier this thanks to the race to develop a coronavirus vaccine, some health care exchange-traded funds are languishing.

Other symbols: BTECPTH
3 years ago - Benzinga

6 Best Biotech ETFs to Buy for Cutting-Edge Growth

Biotech ETFs are, in a word, hot.

3 years ago - Kiplinger

Could Gilead News Be Good For Biotech ETFs?

In a sea of red stocks on Wednesday, as fear grips markets due to another spike in coronavirus cases throughout the country, Gilead Sciences is one of the few bright spots in the stock market.

Other symbols: BBHIBB
3 years ago - ETF Trends

Where to Buy Booming Biotech ETFs

Discover why biotech stocks are surging despite large fund outflows. Monitor these three industry ETFs for "buy the dip" opportunities.

Other symbols: LABUXBI
4 years ago - Investopedia

Investors flee Biotech ETFs as they Lag Bull Market

Many biotech ETFs and other funds have fallen sharply off their highs in recent months.

Other symbols: IBBXBI
4 years ago - Investopedia

3 Charts That Suggest Now Is the Time to Buy Into Biotech

Most of the financial markets have trended lower in recent weeks, but biotech seems to have countered the trend.

Other symbols: INCYIONS
4 years ago - Investopedia